Dr Reddy's CEO Addresses Semaglutide Pipeline Challenges

Dr Reddy's CEO Erez Israeli anticipates strong performance in the second half of FY2026-27 once the company resolves its semaglutide supply issues, noting the highly competitive generics market for the drug.

30 Jul, 06:24 — 30 Jul, 06:24

Post Share

Sources

Showing 1 of 1 sources

bloombergHigh32d ago

Dr Reddy's CEO On Clogged Semaglutide Pipeline

Dr Reddy's CEO Erez Israeli expects a healthy performance in the second half of FY2026-27 once the company resolves the semaglutide issue. Israeli believes the generics market for semaglutide in will be ultra-competitive, with more than 20 companies trying to gain market share. (Source: Bloomberg)

Read full article →

Dr Reddy's CEO Addresses Semaglutide Pipeline Challenges

Sources

Dr Reddy's CEO On Clogged Semaglutide Pipeline

Related Stories

U.S. Treasury Yields Surge as Fed Official Signals Support for Rate Hike

Kalshi Permanently Bans George Santos Over Insider Trading on State of the Union Bets

Dell Stock Gains Investor Focus Ahead of September Earnings Report

Sony and Warner Music Sue Anthropic Over AI Training Copyright Claims